Scientists at Johns Hopkins Medicine have grown tiny brain clusters from Alzheimer's patients' cells, and these mini-brains might help predict who will actually benefit from common antidepressants. Because nothing says 'precision medicine' like a pea-sized organoid.

The researchers used induced pluripotent stem cells from blood samples of Alzheimer's patients and healthy individuals to create hindbrain organoids - pea-sized clusters that produce serotonin. They then dosed these mini-brains with escitalopram oxalate, a popular SSRI, and found that some organoids responded while others didn't. Shocking: people are different.

The organoids also released extracellular vesicles - tiny information-carrying particles - that showed distinct protein changes in Alzheimer's-derived samples. Levels of proteins like RAB3A, NSF, and ATCAY were lower in Alzheimer's organoids, and drug treatment boosted some serotonin-related proteins in certain samples. This variation suggests these vesicles could someday serve as biomarkers to identify which patients might respond to specific treatments.

Study leader Vasiliki Machairaki, Ph.D., hopes to eventually develop more advanced organoids with immune cells and blood-vessel-like networks, and maybe even create a liquid biopsy for Alzheimer's diagnosis and staging. But for now, it's just tiny brains in a dish, doing their best.